Research programme: CNS disease therapeutics - Bristol-Myers Squibb

Drug Profile

Research programme: CNS disease therapeutics - Bristol-Myers Squibb

Alternative Names: Disease activated CNS therapeutics; pH-activated CNS therapeutics

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NeurOp
  • Developer Bristol-Myers Squibb; NeurOp
  • Class Small molecules
  • Mechanism of Action NR2B N-Methyl D-Aspartate receptor modulators; NR2B N-Methyl-D-Aspartate antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cerebral ischaemia; Major depressive disorder; Pain

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cerebral-ischaemia(Prevention) in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Major depressive disorder(Treatment-resistant) in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Pain in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top